Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

175 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phylogeographic variation within the Buff-browed Foliage-gleaner (Aves: Furnariidae: Syndactyla rufosuperciliata) supports an Andean-Atlantic forests connection via the Cerrado.
Cabanne GS, Campagna L, Trujillo-Arias N, Naoki K, Gómez I, Miyaki CY, Santos FR, Dantas GPM, Aleixo A, Claramunt S, Rocha A, Caparroz R, Lovette IJ, Tubaro PL. Cabanne GS, et al. Among authors: naoki k. Mol Phylogenet Evol. 2019 Apr;133:198-213. doi: 10.1016/j.ympev.2019.01.011. Epub 2019 Jan 17. Mol Phylogenet Evol. 2019. PMID: 30660755
The niche and phylogeography of a passerine reveal the history of biological diversification between the Andean and the Atlantic forests.
Trujillo-Arias N, Dantas GPM, Arbeláez-Cortés E, Naoki K, Gómez MI, Santos FR, Miyaki CY, Aleixo A, Tubaro PL, Cabanne GS. Trujillo-Arias N, et al. Among authors: naoki k. Mol Phylogenet Evol. 2017 Jul;112:107-121. doi: 10.1016/j.ympev.2017.03.025. Epub 2017 Apr 3. Mol Phylogenet Evol. 2017. PMID: 28385604 Free article.
A Prospective Phase II Trial of First-line Osimertinib for Patients with EGFR Mutation-positive Non-small Cell Lung Cancer and Poor Performance Status (OPEN/TORG2040).
Fukui T, Mamesaya N, Takahashi T, Kishi K, Yoshizawa T, Tokito T, Azuma K, Morikawa K, Igawa S, Okuma Y, Yamanaka Y, Hosokawa S, Kasai T, Masubuchi K, Nakamichi S, Aga M, Sasaki J, Kada A, Saito AM, Naoki K, Okamoto H; Thoracic Oncology Research Group (TORG). Fukui T, et al. Among authors: naoki k. J Thorac Oncol. 2025 Jan 2:S1556-0864(24)02548-6. doi: 10.1016/j.jtho.2024.12.027. Online ahead of print. J Thorac Oncol. 2025. PMID: 39755169
The Whole Picture of First-Line Osimertinib for EGFR Mutation-Positive Advanced NSCLC: Real-World Efficacy, Safety, Progression Pattern, and Posttreatment Therapy (Reiwa Study).
Watanabe K, Hosomi Y, Naoki K, Nakahara Y, Tsukita Y, Matsumoto H, Yoh K, Fujisaka Y, Takahashi S, Takata S, Usui K, Kishi K, Naka G, Tamano S, Uemura K, Kunitoh H. Watanabe K, et al. Among authors: naoki k. JTO Clin Res Rep. 2024 Sep 7;5(11):100720. doi: 10.1016/j.jtocrr.2024.100720. eCollection 2024 Nov. JTO Clin Res Rep. 2024. PMID: 39416709 Free PMC article.
A phase II study of weekly carboplatin and concurrent radiotherapy in older adults with locally advanced non-small cell lung cancer (LOGIK1902).
Harada T, Sasaki T, Ishii H, Takemoto S, Hisamatsu Y, Saito H, Yoneshima Y, Komiya K, Kashiwabara K, Naoki K, Ogawa T, Takeoka H, Saruwatari K, Ito K, Tsuchiya-Kawano Y, Mizuno K, Shimose T, Shioyama Y, Okamoto I. Harada T, et al. Among authors: naoki k. Thorac Cancer. 2024 Oct;15(29):2128-2135. doi: 10.1111/1759-7714.15444. Epub 2024 Sep 8. Thorac Cancer. 2024. PMID: 39245951 Free PMC article. Clinical Trial.
175 results